spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

HATRIC-based identification of receptors for orphan ligands (small molecules)


HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!

In their latest publication, the Wollscheid group (ETH Zurich, Switzerland) demonstrated how HATRIC-LRC can be used to identify orphan ligand targets from as few as 1 million cells, enabling the LRC technology to be performed on rare primary cells or clinical specimens. What is more, next to de-orphaning proteins, viruses and antibodies, HATRIC-LRC can now be used to identify the unknown targets of small molecules on the cell membrane of living cells in order to elucidate the mode of action of the molecule of interest.

Nadine Sobotzki, Michael A. Schafroth, Alina Rudnicka, Anika Koetemann, Florian Marty, Sandra Goetze, Yohei Yamauchi, Erick M. Carreira & Bernd Wollscheid

Nature Communications, volume 9, Article number: 1519 (2018) doi:10.1038/s41467-018-03936-z,

Published online: 17 April 2018

Abstract

Cellular responses depend on the interactions of extracellular ligands, such as nutrients, growth factors, or drugs, with specific cell-surface receptors. The sensitivity of these interactions to non-physiological conditions, however, makes them challenging to study using in vitro assays. Here we present HATRIC-based ligand receptor capture (HATRIC-LRC), a chemoproteomic technology that successfully identifies target receptors for orphan ligands on living cells ranging from small molecules to intact viruses. HATRIC-LRC combines a click chemistry-based, protein-centric workflow with a water-soluble catalyst to capture ligand-receptor interactions at physiological pH from as few as 1 million cells. We show HATRIC-LRC utility for general antibody target validation within the native nanoscale organization of the surfaceome, as well as receptor identification for a small molecule ligand. HATRIC-LRC further enables the identification of complex extracellular interactomes, such as the host receptor panel for influenza A virus (IAV), the causative agent of the common flu.

 
Print this page
Send to a friend
   
spacer
News and Press Releases

SICK Launches its IntegrationSpace Digital Services Platform

SICK has established a new web-based platform, SICK IntegrationSpace, to be the home for its growing data-based digital software and services portfolio. Seen as a key strategic development for the company, its aim is to align the operating efficiency goals of its customers in automated factory, process and logistics with enterprise-wide business improvement systems.
More info >>


White Papers

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement